中早产儿呼吸暂停延长咖啡因治疗:MoCHA随机临床试验
这项在美国29家医院开展的随机临床试验纳入胎龄29至33周、矫正胎龄33至35周且正在接受咖啡因治疗的中早产儿,评估延长咖啡因治疗至出院后28天是否缩短住院时间。结果发现咖啡因组与安慰剂组随机化后住院天数无差异,咖啡因组呼吸暂停消失更早,但达到生理成熟时间、全口服喂养天数、再入院及患病就诊率无差异,不良事件无统计学显著差异。
要点
- 中早产儿延长咖啡因治疗至出院后28天未缩短随机化后住院时间。
- 咖啡因组呼吸暂停消失更早(6.0天 vs 10.0天,调整中位差-2.7天)。
- 两组达到生理成熟时间、全口服喂养天数、再入院及患病就诊率无差异。
核心结论
- 在中早产儿中,与安慰剂相比继续咖啡因治疗未缩短住院时间。
研究设计与样本
- 2019年2月至2022年12月在美国29家医院开展的随机临床试验,随访于2023年3月20日完成。
- 纳入胎龄29至33周、矫正胎龄33至35周正在接受咖啡因治疗且计划停药、同时接受全喂养(≥120 mL/kg/d)的婴儿。
- 共随机827例婴儿(咖啡因组416例,安慰剂组411例),中位胎龄31周,女性414例(51%),计划样本量878例,在达到预设无效阈值前停止。
- 干预为口服枸橼酸咖啡因(10 mg/kg/d)或安慰剂直至出院后28天。
主要发现
- 随机化后住院天数两组无差异:咖啡因组18.0天(IQR 10至30天)vs 安慰剂组16.5天(IQR 10至27天),调整中位差0天(95%CI -1.7至1.7天)。
- 达到生理成熟天数两组无差异:咖啡因组14.0天 vs 安慰剂组15.0天,调整中位差-1天(95%CI -2.4至0.4天)。
- 咖啡因组呼吸暂停消失更早:6.0天 vs 10.0天,调整中位差-2.7天(95%CI -3.4至-2.0天)。
- 达到全口服喂养天数两组相似:咖啡因组7.5天 vs 安慰剂组6.0天,调整中位差0天(95%CI -0.1至0.1天)。
- 两组再入院率和患病就诊率无差异,两组不良事件无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hospitalization of moderately preterm infants may be prolonged while waiting for apnea of prematurity to resolve after discontinuing caffeine. OBJECTIVE: To evaluate whether extending caffeine treatment reduces the duration of hospitalization. DESIGN, SETTING, AND PARTICIPANTS: From February 2019 to December 2022, this randomized clinical trial in 29 US hospitals enrolled infants born at 29 to 33 weeks' gestation who at 33 to 35 weeks' postmenstrual age were receiving caffeine treatment with plans to discontinue it plus receiving full feeds (≥120 mL/kg/d). Follow-up was completed on March 20, 2023. INTERVENTIONS: Infants were randomized to oral caffeine citrate (10 mg/kg/d) or placebo until 28 days after discharge. MAIN OUTCOMES AND MEASURES: The primary outcome was days to discharge after randomization. Secondary outcomes included days to physiological maturity (apnea free for 5 consecutive days, receiving full oral feeds, and out of the incubator for at least 48 hours), postmenstrual age at discharge, all-cause hospital readmissions, all-cause sick and emergency department visits, safety outcomes, and death. RESULTS: A total of 827 infants (median gestational age, 31 weeks; 414 female [51%]) were randomized (416, caffeine; 411, placebo) out of the 878 planned before reaching the prespecified futility threshold. Days of hospitalization after randomization did not differ between groups (18.0 days [IQR, 10 to 30 days] for caffeine vs 16.5 [IQR, 10 to 27 days] for placebo; adjusted median difference, 0 days [95% CI, -1.7 to 1.7 days]), nor did days to physiological maturity differ (14.0 vs 15.0 days, adjusted median difference, -1 day [95% CI, -2.4 to 0.4 days]). Infants receiving caffeine were apnea free sooner (6.0 vs 10.0 days; adjusted median difference, -2.7 days [95% CI, -3.4 to -2.0 days ]) but had similar days to full oral feeding (7.5 vs 6.0 days, adjusted median difference, 0 days [95% CI, -0.1 to 0.1]). Rates of readmissions and sick visits did not differ between groups. There was no statistically significant difference in adverse events between the 2 groups. CONCLUSIONS AND RELEVANCE: In moderately preterm infants, continuation of caffeine treatment compared with placebo did not shorten hospitalization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03340727.
引用
- Carlo WA, Eichenwald EC, Carper BA, et al. Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial. JAMA. 2025. PMID: 40294395. doi:10.1001/jama.2025.5791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。